FDA NDC Directory · JSON-LD · Markdown

TYSABRI

NDC 64406-008 · HUMAN PRESCRIPTION DRUG · INJECTION

Generic namenatalizumab
Labeler / ManufacturerBiogen Inc.
Marketing categoryBiologic License Application · App BLA125104
Dosage form / routeINJECTION · INTRAVENOUS
Active ingredientsNATALIZUMAB (300 mg/15mL)
Marketing started20041123
Package count1

External sources

Source: openFDA. Public-domain (CC0).